Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.68 |
| ▸ | CA2 | P00918 | 5/20 | 0.68 |
| ▸ | PLK1 | P53350 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | F10 | P00742 | 2/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | CRHBP | P24387 | 1/20 | 0.59 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8717056 | 0.83 | PLK1 (0.80) | CA1CA2PLK1NPC1RAB9A | |
| SCHEMBL11705060 | 0.83 | MAPT (0.79) | CA1CA2PLK1NPC1RAB9A | |
| SCHEMBL837307 | 0.81 | PLK1 (1.00) | CA1CA2PLK1NPC1RAB9A | |
| SCHEMBL942259 | 0.81 | CA1 (1.00) | CA1CA2PLK1NPC1RAB9A | |
| SCHEMBL6387259 | 0.81 | MAPT (0.64) | CA1CA2NPC1RAB9AALDH1A1 | |
| SCHEMBL6242767 | 0.79 | CA1 (0.68) | CA1CA2PLK1NPC1RAB9A | |
| SCHEMBL8582216 | 0.79 | CA1 (0.68) | CA1CA2PLK1NPC1RAB9A | |
| SCHEMBL8579520 | 0.79 | CA1 (0.68) | CA1CA2PLK1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL8880498 | 0.79 | CA1 (0.96) | CA1CA2PLK1NPC1RAB9A | |
| SCHEMBL407188 | 0.79 | CA1 (1.00) | CA1CA2PLK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7268140-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-09-11 | — | — | US | disclosed |
| EP-1727526-A2 | PIPERAZINE UREA DERIVATIVES FOR THE TREATMENT OF ENDOMETRIOSIS | Schering Aktiengesellschaft (DE) | 2006-12-06 | — | — | EP | disclosed |
| EP-1713483-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MULTIPLE MYELOMA | Schering Aktiengesellschaft (DE) | 2006-10-25 | — | — | EP | disclosed |
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | BAUMAN JOHN G | 2006-06-22 | — | — | US | disclosed |
| EP-1660089-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MYOCARDITIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-31 | — | — | EP | disclosed |
| US-6977258-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-20 | — | — | US | disclosed |
| US-6972290-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-06 | — | — | US | disclosed |
| US-4994489-A | Ester derivatives of diarylacetylenes, their compositions and their use in acne treatment | BASF AKTIENGESELLSCHAFT | 1991-02-19 | — | — | US | disclosed |
| EP-0176035-B1 | 1-SUBSTITUTED TETRALIN DERIVATIVES, THEIR PREPARATION AND USE | BASF Aktiengesellschaft (DE) | 1990-06-06 | — | — | EP | disclosed |
| EP-0176032-B1 | TETRALIN DERIVATIVES, THEIR PREPARATION AND USE | BASF Aktiengesellschaft (DE) | 1990-03-07 | — | — | EP | disclosed |
| EP-0176034-B1 | DIARYL ACETYLENES, THEIR PREPARATION AND USE | BASF Aktiengesellschaft (DE) | 1989-08-30 | — | — | EP | disclosed |
| US-4806558-A | Diarylacetylenes and their use in treating acne | BASF AKTIENGESELLSCHAFT (DE) | 1989-02-21 | — | — | US | disclosed |
| US-4801733-A | SKIN DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 1989-01-31 | — | — | US | disclosed |
| US-4760174-A | Tetralin derivatives, their preparation and their use | BASF AKTIENGESELLSCHAFT (DE) | 1988-07-26 | — | — | US | disclosed |
| EP-0176032-A2 | Tetralin derivatives, their preparation and use | BASF Aktiengesellschaft (DE) | 1986-04-02 | — | — | EP | disclosed |
| EP-0176035-A2 | 1-Substituted tetralin derivatives, their preparation and use | BASF Aktiengesellschaft (DE) | 1986-04-02 | — | — | EP | disclosed |
| EP-0176034-A2 | Diaryl acetylenes, their preparation and use | BASF Aktiengesellschaft (DE) | 1986-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | CA1 4558/4885CA2 2886/4885PLK1 3676/4885 |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | CCL2, CCR2, CXCL10 | CA1 4057/4885CA2 3058/4885PLK1 3591/4885 |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | CA1 3517/4885CA2 3996/4885PLK1 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.